Balyasny Asset Management
WX

Balyasny Asset Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Balyasny Asset Management’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-361,301
Closed -$14M – 1478
2015
Q1 		$14M Buy
+361,301
New +$13.9M 0.11% 269

Other funds holding WX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Balyasny Asset Management's WX Position: Q2 2015 in Review

Balyasny Asset Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q2 2015, closing a stake of 361,301 shares — an estimated $14M sold.

Balyasny Asset Management first reported a position in WX in Q1 2015 and held it in 1 quarter. The position peaked at $14M in Q1 2015. 154 funds tracked by Wall St. Rank hold WX as of Q2 2015.

  • Balyasny Asset Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q2 2015 after selling out during the quarter.
  • Balyasny Asset Management sold 361,301 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q2 2015, an estimated $14M.
  • Balyasny Asset Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q1 2015 and held it in 1 quarter.
  • Balyasny Asset Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $14M in Q1 2015.
  • 154 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q2 2015.

Based on Balyasny Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.